RMD May 2024 200.000 call
| Previous close | 20.20 |
| Open | 20.20 |
| Bid | 18.20 |
| Ask | 19.80 |
| Strike | 200.00 |
| Expiry date | 2024-05-17 |
| Day's range | 20.20 - 20.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.53k |
ZacksHaemonetics (HAE) Stock Up 10.9% YTD: Will the Rally Continue?
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.
GlobeNewswireATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- When: May 17–22, 2024Where: San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101 Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101 Research: 26 ResMed-supported abstracts will be presented at ATS. Full list below. Highlights: Treatment of Sleep-Disordered Breathing with Adaptive Servo-Ventilation (READ-ASV) in Opioid Users – a European Registry Sunday May 19, 2024, 9:15 a.m. - 11:15 a.m., SDCC 32A-BPresented
ZacksWhat Makes ResMed (RMD) a New Strong Buy Stock
ResMed (RMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
